Indiana University chemist Richard DiMarchi has been named a co-recipient of the 2026 Broermann Medical Innovation Award, an international prize worth €1 million that honors research with significant impact on human health, according to an IU news release.

DiMarchi, a Distinguished Professor of Chemistry and Gill Chair in Biomolecular Sciences at IU Bloomington, shares the award with Svetlana Mojsov of The Rockefeller University and Matthias H. Tschöp, president of Ludwig Maximilian University in Munich. The three scientists were recognized for discoveries that contributed to the development of modern GLP-1-based therapies for obesity and diabetes, the university reported.

The award was presented Nov. 17 during a ceremony at the Hessian State Chancellery in Wiesbaden, Germany, by Boris Rhein, minister-president of the German state of Hesse.

GLP-1 drugs, such as Ozempic and Wegovy, have reshaped treatment for obesity and diabetes in recent years, becoming some of the most widely prescribed medications globally. DiMarchi's work helped lay the chemical and biological groundwork for these therapies, IU said.

"For decades Richard DiMarchi has advanced discoveries that connect fundamental science to transformational patient treatments," Caroline Chick Jarrold, interim executive dean of the College and the Herman B Wells Professor of Chemistry, said in the release. "This global recognition reflects the extraordinary impact of his work on biomedical research, and on the health and wellness of millions of people around the world."

DiMarchi is widely regarded as one of the world's leading peptide chemists. He earned his Ph.D. in chemistry from IU in 1979 and then built a career spanning academia, industry and entrepreneurship, the university noted. After early academic appointments, he spent more than two decades at Eli Lilly and Company, where he played a key role in developing rDNA-derived human insulin and insulin analogs — advances that made diabetes treatments safer and more precisely matched to patients' needs, according to IU.

He later returned to IU, where he continues to teach, pursue novel approaches in peptide synthesis, explore new mechanisms in disease management and collaborate on translating findings into breakthrough medicines, the release stated.

"In the last decade, based upon a half century of research, we have progressed with incretin-based medicines to transform the management of excess body weight analogous to historical treatment of excess glucose, cholesterol and blood pressure," DiMarchi said in the release. "It is providing a transformative advance in public health and patient well-being."

DiMarchi holds more than 100 patents and has co-founded eight biotechnology companies, helping translate fundamental research into medicines with global impact, IU reported. He is a member of the National Inventors Hall of Fame and the National Academy of Medicine.

Werner Seeger, chair of the Broermann Award jury, said in the release: "The work of this year's laureates powerfully proves how pioneering scientific research transforms into medical reality. Their discoveries surrounding GLP-1 and polyagonists have fundamentally redefined obesity and diabetes care, offering real hope to millions worldwide."

Established in 2024 by the Broermann Foundation and named for physician and entrepreneur Bernard große Broermann, the Broermann Medical Innovation Award ranks among the highest-endowed medical prizes in the world, according to IU.

For students, the award underscores the potential of a career in academic research to produce real-world medical breakthroughs. DiMarchi's path — from IU Ph.D. student to industry scientist at a major pharmaceutical company and back to academia — also illustrates how a research career can bridge the lab, the clinic and the marketplace.